Clinical Trial · NCT07859046

18F-FES PET/CT in the Treatment Planning, and Response Assessment of ER-Positive Breast Cancer

Overview

This study uses FES PET/CT imaging to evaluate estrogen receptor-positive breast cancer. FES PET/CT is a type of imaging that can show whether breast cancer cells have estrogen receptors. The purpose of this study is to see how well FES PET/CT can help doctors: (1) diagnose ER-positive breast cancer, (2) plan the best treatment, and (3) check how well treatment is working. Participants will undergo FES PET/CT scans as part of their regular cancer care or study procedures. The results may help improve how doctors use imaging to guide treatment decisions for patients with ER-positive breast cancer.

Sponsor

Hunan Cancer Hospital

ClinicalTrials.gov

NCT07859046

Drug / Compound

FDG

Isotope(s):

Target(s):

Glucose Transport

Ligand Class: Small Molecules

FES

Isotope(s):

Target(s):

Estrogen Receptor

Ligand Class: Small Molecules

Eligibility

Inclusion

Inclusion criteria not yet provided.

Exclusion

(1)patients with more than two primary tumors; (2) incomplete clinical or pathological records; and (3) inability to complete imaging studies